Stockalyze
Example report. Sign up to run the same analysis on any ticker.
ASML logoASMLEquity research

Report date: 2026-11-16

$1267.74-88.46 (-6.52%)Live · delayed quote, informational only

Analysis focus

Provide a balanced, comprehensive analysis: fundamentals and valuation, the Wall Street view, technical posture, and the key forward risks and catalysts.

Summary

Fundamentally, ASML's latest quarter was strong, but the headline overstates it. Q3 2026 net sales were €11,662 million, up from €9,326 million in Q2. Gross margin was 57.5%, net income €4,960 million and basic EPS €12.95, on 113 new and 8 used lithography systems and €3,289 million of Installed Base Management sales [1]. Management guided Q4 net sales to €14.2–15.2 billion at about 57% gross margin and full-year 2026 to €44–45 billion at about 56%. The CEO said planned 2027–2028 supply 'will not fully meet the demand of our customers', and ASML plans to raise low-NA EUV and DUV immersion capacity by 30% in 2027 [2]. A secondary source could not match the Q4 guide to the release [19], but the primary 6-K contains it [2]. The beat needs normalizing. Q3 net income included a gain of roughly €500 million tied to ASML's Mistral AI stake, about 10% of net income [21]. Operating income was about €5.2 billion, so the jump in basic EPS from €7.59 in Q2 to €12.95 in Q3 likely overstates core earnings growth [15]. The balance sheet is net cash. Trailing free cash flow was $23.34 billion against $2.24 billion of total debt. Cash and short-term investments were €12,735 million at quarter-end, after about €4.1 billion of Q3 buybacks [18]. An interim dividend of €1.88 was paid on November 4 (trailing yield about 0.53%) [8]. ASML does not report quarterly bookings, so customer interest in 2029–2030 orders is not firm backlog [2][19]. Valuation and the Wall Street view. At the $1,495.16 close on November 13, ASML traded at 38.77x trailing and 23.44x forward earnings, 29.99x EV/EBITDA and 22.47x book, with a market cap of $564.94 billion [16]. It trades at a premium to Applied Materials on every multiple compared: 29.36x trailing, 19.31x forward, 24.43x EV/EBITDA and 11.25x book, with similar dividend yields (0.53% vs 0.57%) [17]. Against its own history, the trailing P/E and EV/EBITDA sit at the top of the FY2022–FY2025 range (34.3–37.0x and 27.0–28.8x) but below the FY2021 peak of 48.8x and 41.0x, while P/B is above FY2023–FY2025 levels of 14.4–20.0x [22]. MarketScreener's estimates put the P/E at 32.1x for 2026E and 23.5x for 2027E, but that page may be stale [16]. The sell-side remains constructive. MarketBeat shows a 'Moderate Buy' consensus across 24 ratings (2 Strong Buy, 17 Buy, 2 Hold, 3 Sell) with a $2,204.71 average target [3]. That is about 44% above the November 11 mid-day price of $1,534.42 [9]. StockAnalysis puts the average near $2,138, and target lows run $1,415–$1,450 [14]. Named bank targets include Bernstein at $2,623, Wells Fargo at $2,500, JPMorgan at $2,350 (cut from $2,400 on October 15), and RBC and Argus at $2,100 each [10]. Activity in the last 90 days was mostly reiterations plus JPMorgan's $50 trim, with no new rating changes found from Goldman Sachs, Morgan Stanley, BofA or Barclays [11]. A large gap between price and target usually means analysts have not yet caught up with a falling price, not that upside is confirmed [9]. Technical posture and the balanced case. The stock's near-term trend is weak. It sits about 25% below its 52-week high of $1,999.96, though it is up 44.14% over 52 weeks from a low of $946.11 [5]. The price is below both the 50-day average (about $1,660) and the 200-day (about $1,602). The 50-day is still above the 200-day, so the long-term structure holds for now while the near-term trend has broken down [6][4]. The shares fell about 13.6% over 30 days into late October [7]. They dropped 6.67% on November 5 on export-control worries, customer capex caution and higher bond yields, then rose 6.12% on November 9 in an AI rally [7]. RSI(14) has recovered to about 42 from oversold readings of about 27–29 around November 4–5 [12]. Near-term support is around $1,355. Resistance sits at the 200-day and 50-day averages (about $1,600 and $1,660) and at the roughly $2,000 52-week high [13]. The case for caution: a premium multiple against both its peer and its own recent history [17][22], a broken short-term trend [6], a one-time gain inflating Q3 earnings [21], and risks from export controls, tariffs and the gap between stated demand and firm orders [23][7]. The case for patience: confirmed Q4 and full-year guidance, a supply-constrained outlook for 2027–28 with planned capacity growth [2], strong cash generation and buybacks [18], a forward P/E well below the trailing one [16], and catalysts named in the coverage, including AI-driven memory and logic spending and High-NA EUV adoption [23].

Findings (23)

ASML reported Q3 2026 total net sales of €11,662 million, up from €9,326 million in Q2 2026, with a gross margin of 57.5%, net income of €4,960 million and basic EPS of €12.95 (diluted €12.93); Installed Base Management sales were €3,289 million and the company sold 113 new and 8 used lithography systems.

High confidence

ASML's 6-K earnings release filed with the SEC (primary source) lists these exact Q3 2026 figures, and the company press release republished on Seeking Alpha matches them.

ASML guided Q4 2026 net sales to €14.2–15.2 billion at a gross margin of about 57%, and full-year 2026 net sales to €44–45 billion at a gross margin of about 56%; the CEO said planned 2027–2028 supply 'will not fully meet the demand of our customers', and the company plans a 30% increase in low-NA EUV and DUV immersion capacity in 2027.

High confidence

The guidance and CEO Christophe Fouquet's capacity comments appear in the primary 6-K release. The release does not disclose a quarterly net bookings figure, so customer interest in 2029–2030 orders should not be read as firm backlog.

MarketBeat lists ASML's ADR (NASDAQ: ASML) consensus as "Moderate Buy" across 24 ratings (2 Strong Buy, 17 Buy, 2 Hold, 3 Sell), with an average 12-month price target of $2,204.71.

High confidence

MarketBeat's November 9 and November 11, 2026 alerts give the same rating breakdown and the same $2,204.71 average target. Other aggregators differ: Investing.com shows an average of about $2,137 from 40 Buy, 3 Hold and 1 Sell over the last three months, and AlphaSpread shows €2,127.38 from 39 analysts for the Euro listing. The differences come from the share class, the set of analysts counted, and the snapshot date. No median target was found in the sources reviewed.

Technically, ASML at ~$1,534 sits below both its 50-day simple moving average ($1,669.83) and its 200-day simple moving average ($1,601.18), even after bouncing about 6% on November 9 from a $1,424.75 close.

High confidence

MarketBeat gives the November 11 averages of $1,669.83 (50-day) and $1,601.18 (200-day). Its November 9 alert shows a 6.2% gain to $1,513.25 from $1,424.75 on above-average volume (about 2.19M shares vs. 1.75M average). Trading below both averages points to a recent downtrend, though the 50-day average is falling toward the 200-day.

ASML closed at $1,495.16 on November 13, 2026, about 25% below its 52-week high of $1,999.96 and up from its 52-week low of $946.11, with a 52-week price change of +44.14%; none of the sources reviewed gave a 6-month return.

High confidence

StockAnalysis lists the Nov 13 close of $1,495.16, the 52-week range of $946.11 to $1,999.96 and a 52-week price change of +44.14% (statistics page updated Nov 15, 2026). The quote and statistics pages reviewed did not show a 6-month return.

The share price ($1,495) is below both the 50-day simple moving average (about $1,660) and the 200-day (about $1,602), while the 50-day is still above the 200-day.

High confidence

StockAnalysis reports a 50-day MA of $1,660.49 and a 200-day MA of $1,602.21. TipRanks shows similar values ($1,689.58 and $1,596.22) and flags both as sell signals with price below them. So the long-term trend structure is intact for now, but the near-term trend has broken down.

The stock fell about 13.6% over 30 days into late October and stayed volatile in November. It fell 6.67% on Nov 5 amid a U.S. chip sell-off, export-control worries and rising bond yields, then rose 6.12% on Nov 9 in a broad AI-stock rally.

Medium confidence

Tickeron reports a roughly -13.6% 30-day move (from $1,811.67 to $1,565.90) and about a 5% drop on Oct 30 after Intel and Amazon news. TradingKey attributes the Nov 5 drop to China export-control scrutiny, customer capex caution, higher yields and a sequential dividend cut. StockAnalysis's news feed links the Nov 9 rebound to an AI-stock rally.

ASML declared an interim dividend of €1.88 per share, payable November 4, 2026, for a trailing yield of about 0.53% and reported year-over-year dividend growth of 26.27%; meanwhile the stock is in a weak technical posture, trading at $1,495.16, below its 50-day ($1,660.49) and 200-day ($1,602.21) moving averages with an RSI of 42.19, after a 6.6% one-day drop on October 30.

Medium confidence

The €1.88 interim dividend is in the primary release, and the yield, dividend growth, moving averages and RSI come from StockAnalysis as of Nov 13. The October 30 drop is reported by Debelegger. Analyst targets conflict across aggregators, for example StockAnalysis's €1,539 average from 44 analysts versus MarketBeat's $1,970 consensus in July, so no single consensus target is cited with high confidence.

In mid-day trading on November 11, 2026, ASML traded at $1,534.42, about 30% below the $2,204.71 average target, which implies roughly 44% upside to consensus.

High confidence

MarketBeat reports the $1,534.42 mid-day price (up 1.8% from a $1,507.85 prior close) next to the $2,204.71 consensus target. The upside figure is calculated: $2,204.71 / $1,534.42 − 1 ≈ 43.7%. Such a wide gap usually means the price has fallen faster than analysts have revised their targets, which matches the pullback described in the technical finding.

Major-bank targets on record are all well above the ~$1,534 price: Bernstein $2,623 (+71%, raised July 6), Wells Fargo $2,500 (+63%, raised from $2,200 on July 16), JPMorgan $2,350 (+53%, cut from $2,400 on October 15), and RBC and Argus at $2,100 each (+37%).

Medium confidence

The MarketBeat alerts list Wells Fargo's raise to $2,500 (Overweight), JPMorgan's cut from $2,400 to $2,350 (Overweight), RBC's $2,100 Outperform and Argus's $2,100. MarketBeat's July 16 piece records JPMorgan's earlier raise from $2,200 to $2,400 and Bernstein's raise from $1,971 to $2,623 (Outperform). Upside percentages are calculated against $1,534.42. Confidence is medium because the Wells Fargo and Bernstein targets are about four months old and may have changed since.

In the last 90 days (since about August 18, 2026) the documented actions were mostly reiterations and one trim: Cantor Fitzgerald reiterated Overweight (September 14), RBC restated Outperform at $2,100 (October 7), Citigroup reissued Buy (October 15), and JPMorgan cut its target by $50 to $2,350 (October 15). No new Goldman Sachs, Morgan Stanley, BofA or Barclays rating changes were found in this window.

Medium confidence

MarketBeat lists these dated actions; October 15 falls on a Thursday in 2026, which matches the listing. The latest Goldman Sachs action found is an April 15, 2026 Buy reiteration, and Morgan Stanley's latest is a July 7, 2026 Overweight reaffirmation. Barclays (Equal Weight, €650) and Jefferies (Hold, €690) downgrades also turned up, but their euro targets are less than half the current share price, so they appear to be from an earlier cycle and are left out as stale. The only true rating upgrade in the window came from a quant service (Wall Street Zen, Hold to Buy on October 17), not from a bank.

RSI(14) is in neutral territory at about 42 as of mid-November 2026, recovering from oversold readings of about 27 to 29 around November 4–5, 2026.

Medium confidence

StockAnalysis lists an RSI of 42.19 (updated Nov 15). TradingKey reported an RSI of 28.957 on Nov 5 after a 6.67% one-day drop, and Financhill showed an RSI near 27 with the price around $1,356. These are secondary aggregators and their readings vary by date.

Near-term support sits around the early-November low of roughly $1,355, overhead resistance is at the 200-day (about $1,600) and 50-day (about $1,660) averages, and major resistance is the $2,000 area at the 52-week high.

Medium confidence

Tickeron names the roughly $2,000 52-week-high zone as major resistance and the early-November low near $1,355 as near-term support. Financhill's roughly $1,356.65 low-RSI reading confirms that trough. The moving-average levels from StockAnalysis act as nearer overhead resistance.

The sell-side remains constructive despite the drawdown. Average 12-month targets range from about $2,138 (StockAnalysis, 41 analysts) to about $2,205 (MarketBeat, 24 analysts), with target lows of $1,415 to $1,450. At $1,495 the stock trades at 38.8x trailing and 23.4x forward earnings.

Medium confidence

StockAnalysis shows a consensus near $2,138 and P/E ratios of 38.77 trailing and 23.44 forward. MarketBeat's Nov 7 alert gives a $2,204.71 consensus, a $1,415 to $2,623 range, and notes JPMorgan cutting its target to $2,350. Targets differ by aggregator.

Q3 2026 net income of about €5.0 billion appears to include non-operating equity-investment gains that cannot be separated from the operating result using the filing: operating income was about €5.2 billion, and a normal tax charge would leave net income well below €5.0 billion, so the jump in basic EPS from €7.59 in Q2 to €12.95 in Q3 probably overstates core earnings growth.

Medium confidence

A secondary analysis says Q3 net income includes equity investment gains that should be kept separate from operating results and puts operating income near €5.2 billion. The primary release does not break out the gain, so its size is inferred, not disclosed.

At the close on November 13, 2026, ASML (NASDAQ) traded at $1,495.16, with a market cap of $564.94 billion, enterprise value of $553.06 billion, trailing P/E of 38.77, forward P/E of 23.44, P/B of 22.47 and EV/EBITDA of 29.99; MarketScreener's Euronext estimates put P/E at 32.1x for 2026E and 23.5x for 2027E.

Medium confidence

StockAnalysis lists these multiples as of the Nov 13 close, the latest data available, not Nov 16. MarketScreener shows a €512 billion market cap and €498 billion EV but marks the page 'inactive instrument', so its figures may be stale. Forward P/E varies widely by estimate year and source.

Against peer Applied Materials (AMAT: $370.50 on Nov 13, 2026, market cap $294.03 billion), ASML trades at a premium on every multiple compared: trailing P/E 38.77 vs 29.36, forward P/E 23.44 vs 19.31, EV/EBITDA 29.99 vs 24.43, and P/B 22.47 vs 11.25, with similar dividend yields (0.53% vs 0.57%).

Medium confidence

Both companies' statistics pages on the same aggregator show these figures as of the Nov 13, 2026 close, so the comparison uses the same methodology and date.

ASML's balance sheet is net cash: trailing-twelve-month free cash flow was $23.34 billion (operating cash flow $25.06 billion) against total debt of $2.24 billion, and the company held €12,735 million in cash and short-term investments at the end of Q3 2026 while repurchasing about €4.1 billion of shares in the quarter.

Medium confidence

The cash balance, the €4.1 billion Q3 buyback under the 2026–2028 program, and the dividend come from the primary 6-K. The free cash flow and debt totals come from the aggregator, because the release did not state them.

ASML reported record Q3 2026 net sales of about €11.7 billion, a 57.5% gross margin and net income of about €5 billion, and guided full-year 2026 net sales to €44–45 billion at a gross margin of about 56%.

Medium confidence

Secondary analyses of the October 2026 release report €11.7B in sales, near the high end of guidance, with Installed Base Management at €3.3B (above guidance) lifting the margin. They also report the full-year guidance. One reported Q4 revenue guide of €14.2–15.2B could not be confirmed against ASML's own release. The release reportedly gave no quarterly bookings figure, and customer interest in 2029–2030 orders is not the same as firm bookings. No one-time items were flagged; the margin uplift is attributed to service and upgrade revenue mix, and should be checked against ASML's primary filing.

ASML trades at a trailing P/E of about 37.8 and a market cap of about $591 billion, with the consensus full-year EPS estimate at $46.54.

Medium confidence

MarketBeat lists a P/E of 37.77 and a market cap of $591.40B on November 11, and a current-year EPS estimate of 46.54 on November 9. At $1,534 that is roughly 33x the current-year estimate (calculated). A peer comparison and ASML's own 5-year multiple history were not available within the search budget, so it is not established whether this multiple is high or low by those measures.

The Q3 2026 earnings beat was partly due to a one-time item: net income of about €5.0B included a roughly €500M gain tied to ASML's Mistral AI stake, which should be stripped out when judging underlying operating performance.

Medium confidence

The earnings call transcript summary says Q3 net income of about €5.0B included a roughly €500M Mistral AI-related gain. Removing it cuts net income by about 10%, so the size of the headline EPS beat overstates the operating beat.

ASML's current trailing P/E of 38.77 and EV/EBITDA of 29.99 sit at the upper end of its FY2022–FY2025 range (P/E 34.3–37.0, EV/EBITDA 27.0–28.8) but below FY2021's peak of 48.8x P/E and 41.0x EV/EBITDA, while its P/B of 22.47 is above FY2023–FY2025 levels (14.4–20.0).

Medium confidence

StockAnalysis's annual ratios table gives fiscal-year-end multiples for FY2021–FY2025 and a current column dated Nov 13, 2026. The data comes from an aggregator, not company filings.

Downside risks named in the coverage include semiconductor export controls and tariffs, the gap between customers' stated long-dated demand and firm orders, and a possible lack of capacity for 2027–28; the upside catalysts named are AI-driven memory and logic investment and High-NA EUV adoption.

Low confidence

Secondary commentary says ASML expects supply to trail 2027–28 demand. Separate Simply Wall St community narratives argue the bear case (export controls and tariffs) and the bull case (High-NA EUV and AI). Confidence is low because these are opinion pieces, not primary disclosures.

Sources (32)

Caveats

Time sensitivity: prices and multiples come from the November 13, 2026 close [5][16] or from November 9–11 intraday snapshots [4][9], not from November 16. Figures differ by date and source, for example market cap of $564.94B [16] vs $591.40B [20] and trailing P/E of 38.77 [16] vs 37.77 [20]. Consensus targets are not consistent across aggregators. MarketBeat shows $2,204.71 from 24 ratings [3]. StockAnalysis is cited at about $2,138 from 41 analysts in one finding [14] but at €1,539 from 44 analysts in another [8]. Investing.com shows about $2,137 and AlphaSpread €2,127.38 for the Euro listing [3]. No median target was found [3]. Some bank targets are about four months old (Bernstein, Wells Fargo) [10]. The Barclays and Jefferies euro targets were left out as stale [11]. The Mistral AI gain (about €500M) comes from a transcript summary and the operating-income estimate from a secondary analysis. The primary filing does not break out the gain, so the normalized earnings figure is approximate [15][21]. One source cites a 'sequential dividend cut' [7] while another reports 26.27% year-over-year dividend growth [8]. Interim dividends can differ in timing from final dividends, so this was not reconciled. Free cash flow, debt, multiples, moving averages, RSI and historical ratios come from secondary aggregators, not company filings [6][12][18][22]. Technical readings vary by provider and date [6][12]. Risk and catalyst themes rest on low-confidence opinion pieces [23]. Not covered: quarterly net bookings (not disclosed) [2], 6-month return [5], customer or regional revenue mix, a detailed segment breakdown of EUV versus DUV, the size of China exposure, and a full peer set beyond Applied Materials. This report presents evidence only and is not a buy, sell or hold recommendation.

This report is for informational purposes only and is not investment advice. No buy / sell / hold recommendation is made or implied.

More research reports

Recent reports from the same pipeline. See all examples

Want this on your watchlist?

Add your own focus, pick a delivery speed, and get a source-verified report like this one.